ATNAA
Key Takeaways
- Set-aside for No Set Aside businesses
- Work to be performed in PHILADELPHIA, PA
- Industry: Biological Product (except Diagnostic) Manufacturing
- This is market research - no award at this stage
Contract Details
- Notice ID
- SPE2DP-26-D-0001
- Opportunity Type
- Sources Sought
- Agency
- DEPT OF DEFENSE
- Sub-Agency
- DEFENSE LOGISTICS AGENCY
- Office
- DLA TROOP SUPPORT
- Posted Date
- Thursday, September 17, 2026
- Response Deadline
- Friday, October 2, 2026
- PSC Code
- 6505
- Set-Aside
- No Set Aside
- Place of Performance
- PHILADELPHIA, PA, 19111
- Status
- Active
Description
Antidote Treatment Nerve Agent Auto-Injector Request For Information (RFI) This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Item: ANTIDOTE TREATMENT, NERVE AGENT, Automatic, Dual-Chamber, Pralidoxime Chloride Injection, 300 mg per mL, 2 mL, and Atropine Injection, 2.99 mg per mL, 0.7 mL NSN: 6505-01-362-7427 Description: The Defense Logistics Agency Troop Support has a requirement for the supply of Antidote Treatment Nerve Agent Auto-Injector (ATNAA). ATNAA shall be made in accordance with MPID Number 6 dated May 2, 2019. ----------------------------------------------------- The Defense Logistics Agency Troop Support is seeking sources capable of providing the Antidote Treatment Nerve Agen
Why This Opportunity Matters
The Department of DEFENSE is conducting market research to identify potential sources for biological product (except diagnostic) manufacturing with a set-aside for No Set Aside businesses in PHILADELPHIA, PA. Responding to this notice helps ensure your company is considered for the eventual solicitation.
Similar Opportunities
Browse Related
Looking for more opportunities?
Browse our full directory of government contracts
